{"title": "Wegovy - European Medicines Agency", "author": "EMA; COMM; DG; UNIT", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy", "hostname": "europa.eu", "description": "Wegovy", "sitename": "European Medicines Agency", "date": "2021-11-11", "cleaned_text": "Overview Wegovy is used together with diet and physical activity to help people to lose weight and keep their weight under control. It is used in adults who have: a BMI of 30 kg/m\u00b2 or greater (obesity) or a BMI of at least 27 kg/m\u00b2 but less than 30 kg/m\u00b2 (overweight) who have weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood, breathing problems during sleep called 'obstructive sleep apnoea' or a history of heart attack, stroke or blood vessel problems). It is also used in adolescents from 12 years of age whose BMI is at or above the 95th percentile for their age and gender (obesity) and who weigh more than 60 kg. BMI (body mass index) is a measure of your weight in relation to your height. A BMI at the 95th percentile means that it is greater than that of 95% of people of the same age and gender. Wegovy contains the [active substance](/en/glossary/active-substance) semaglutide. - List item Wegovy EPAR KB) First published: Last 09/06/2023 EMA/162766/2023 - - List item Wegovy : EPAR - Risk management plan summary (PDF/271.55 code|| | A10BJ06 |Additional monitoring|| | This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under |Publication details| |Marketing-authorisation holder|| | Novo Nordisk A/S |Revision|| | 3 |Date of issue of marketing authorisation valid throughout the European Union|| | 06/01/2022 |Contact address|| Novo - II/0009 This medicine's [product information](/en/glossary/product-information) available in all official EU languages. Select 'available languages' to access the language you need. [Product information](/en/glossary/product-information) contain: [summary of product characteristics](/en/glossary/summary-product-characteristics)(annex I); - manufacturing authorisation holder responsible for batch release (annex IIA); - documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the [Veterinary Medicines Information website](https://www.medicinesinfo.eu/). Pharmacotherapeutic group Antiobesity preparations, excl. diet products Therapeutic indication Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of - 30 kg/m\u00b2 (obesity), or - 27 kg/m\u00b2 to <30 kg/m\u00b2 (overweight) in the presence of at least one weight-related comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Adolescents (12 years) Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity* and body weight above 60 kg. Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. *Obesity (BMI 95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) (see Table 1 in 4.1 of SmPC). Table 1 BMI cut-off points for obesity (95th percentile) by sex and age for paediatric patients aged 12 and older (CDC criteria) "}